JP2010501479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501479A5 JP2010501479A5 JP2009524014A JP2009524014A JP2010501479A5 JP 2010501479 A5 JP2010501479 A5 JP 2010501479A5 JP 2009524014 A JP2009524014 A JP 2009524014A JP 2009524014 A JP2009524014 A JP 2009524014A JP 2010501479 A5 JP2010501479 A5 JP 2010501479A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- amino acid
- shows
- amino acids
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83703006P | 2006-08-10 | 2006-08-10 | |
| US91747607P | 2007-05-11 | 2007-05-11 | |
| PCT/US2007/075728 WO2008019395A2 (en) | 2006-08-10 | 2007-08-10 | Compounds for improving learning and memory |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010501479A JP2010501479A (ja) | 2010-01-21 |
| JP2010501479A5 true JP2010501479A5 (enExample) | 2010-07-01 |
Family
ID=39033625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524014A Pending JP2010501479A (ja) | 2006-08-10 | 2007-08-10 | 学習および記憶を改善するための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080108568A1 (enExample) |
| EP (1) | EP2061314A4 (enExample) |
| JP (1) | JP2010501479A (enExample) |
| AU (1) | AU2007281701A1 (enExample) |
| CA (1) | CA2659289A1 (enExample) |
| WO (1) | WO2008019395A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2638802A1 (en) * | 2006-01-27 | 2007-10-25 | Translational Genomics Research Institute | Genes affecting human memory performance |
| EP2285217A4 (en) * | 2008-05-12 | 2011-06-08 | Amnestix Inc | CONNECTIONS TO IMPROVE LEARNING AND MEMORY |
| WO2010132128A1 (en) * | 2009-05-14 | 2010-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease |
| EP2354789A1 (en) * | 2010-02-08 | 2011-08-10 | Sygnis Bioscience GmbH & Co. KG | Method for the identification of memory modulating compounds by assessing KIBRA expression |
| US20120010196A1 (en) * | 2010-04-02 | 2012-01-12 | Qin Quingyu | Methods of treating neurodegenerative disorders and diseases |
| WO2012006640A2 (en) * | 2010-07-09 | 2012-01-12 | Translational Genomics Research Institute | Compositions and methods useful in enhancement of memory |
| WO2013041238A1 (en) * | 2011-09-21 | 2013-03-28 | Sygnis Bioscience Gmbh & Co. Kg | Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders |
| KR102276424B1 (ko) | 2014-10-06 | 2021-07-12 | 삼성전자주식회사 | 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도 |
| EP3367898A4 (en) * | 2015-10-27 | 2019-07-03 | HRL Laboratories, LLC | TRANSCRANIAL CONTROL OF THE PROCEDURAL MEMORY BACKWARD FOR SENSITIVITY DETECTION |
| US11587644B2 (en) | 2017-07-28 | 2023-02-21 | The Translational Genomics Research Institute | Methods of profiling mass spectral data using neural networks |
| MX2022008513A (es) | 2020-01-09 | 2022-08-08 | Woolsey Pharmaceuticals Inc | Metodos para tratar la deambulacion asociada con la demencia cortical. |
| US11642352B2 (en) | 2020-03-25 | 2023-05-09 | Woolsey Pharmaceuticals, Inc. | Methods of treating wandering in Lewy dody dementia |
| WO2021216139A1 (en) * | 2020-04-23 | 2021-10-28 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| CN116249532A (zh) * | 2020-06-15 | 2023-06-09 | 乌尔塞制药公司 | 使用Rho激酶抑制剂治疗血管性痴呆的方法 |
| MX2023000600A (es) * | 2020-07-14 | 2023-02-13 | Woolsey Pharmaceuticals Inc | Metodos de tratamiento de proteinopatias. |
| CN112010805B (zh) * | 2020-08-26 | 2023-12-05 | 山东威高药业股份有限公司 | 一种盐酸法舒地尔的精制方法 |
| WO2022046158A1 (en) * | 2020-08-27 | 2022-03-03 | Woolsey Pharmaceuticals, Inc | Methods of treating age-related cognitive decline |
| MX2023002396A (es) * | 2020-08-28 | 2023-05-10 | Woolsey Pharmaceuticals Inc | Métodos para tratar el deterioro cognitivo relacionado con la edad. |
| EP4232041A4 (en) | 2020-10-22 | 2024-09-25 | Woolsey Pharmaceuticals, Inc. | Methods of treating 4-repeat tauopathies |
| US20240423998A1 (en) | 2021-11-29 | 2024-12-26 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| CN114457154B (zh) * | 2022-04-13 | 2022-06-28 | 山东第一医科大学附属省立医院(山东省立医院) | KIBRA rs17070145检测试剂在制备嗅觉功能评价试剂盒中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993054A (ja) * | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| JPH0667926B2 (ja) * | 1985-11-12 | 1994-08-31 | 旭化成工業株式会社 | 環状のイソキノリンスルホンアミド誘導体 |
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| JP3464012B2 (ja) * | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| CN1080721C (zh) * | 1995-07-03 | 2002-03-13 | 旭化成株式会社 | 1-(5-异喹啉磺酰基)高哌嗪盐酸盐水合物 |
| CN100444843C (zh) * | 1998-08-10 | 2008-12-24 | 旭化成制药株式会社 | 法舒地尔盐酸盐缓释口服制剂 |
| US7655423B2 (en) * | 1999-06-14 | 2010-02-02 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
| US20020173535A1 (en) * | 2001-02-07 | 2002-11-21 | Renshaw Perry F. | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
| ATE439797T1 (de) * | 2001-04-27 | 2009-09-15 | Cold Spring Harbor Lab | Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität |
| DE10153605A1 (de) * | 2001-11-02 | 2003-05-28 | Morphochem Ag Komb Chemie | Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens |
| WO2004105757A2 (en) * | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| WO2005117896A1 (de) * | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| CA2638802A1 (en) * | 2006-01-27 | 2007-10-25 | Translational Genomics Research Institute | Genes affecting human memory performance |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
-
2007
- 2007-08-10 WO PCT/US2007/075728 patent/WO2008019395A2/en not_active Ceased
- 2007-08-10 EP EP07840881A patent/EP2061314A4/en not_active Withdrawn
- 2007-08-10 CA CA002659289A patent/CA2659289A1/en not_active Abandoned
- 2007-08-10 US US11/837,326 patent/US20080108568A1/en not_active Abandoned
- 2007-08-10 AU AU2007281701A patent/AU2007281701A1/en not_active Abandoned
- 2007-08-10 JP JP2009524014A patent/JP2010501479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010501479A5 (enExample) | ||
| US12558324B2 (en) | Application of R-ketamine and salt thereof as pharmaceuticals | |
| US8088951B2 (en) | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss | |
| US11278550B2 (en) | Compositions and methods for the treatment of Prader-Willi syndrome | |
| US9402826B2 (en) | Neuronal pain pathway modulators | |
| US20120295853A1 (en) | Neuronal pain pathway | |
| US20210277478A1 (en) | Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype | |
| CN109475539B (zh) | 帕金森氏病的治疗 | |
| US10676747B2 (en) | Methods for improving cognitive function via modulation of quinone reductase 2 | |
| CN107249583A (zh) | 乳酸脱氢酶抑制剂以及含有该抑制剂的抗癫痫剂 | |
| JP2021530541A5 (enExample) | ||
| AU2026201900A1 (en) | Optimized sigma-1 agonist method of responder selection and treatment | |
| JP2012508249A5 (enExample) | ||
| JP2015535247A5 (enExample) | ||
| JP2005508872A5 (enExample) | ||
| JP2011518168A5 (enExample) | ||
| JP2023088996A (ja) | 癌治療 | |
| JP2007527859A (ja) | グリコーゲンシンターゼキナーゼ−3阻害剤 | |
| JP2024543963A (ja) | 高い安定性及び遺伝子サイレンシング活性を有する低分子干渉rna分子のための修飾パターン | |
| PT1926483E (pt) | Tratamento de doenças autoimunes | |
| KR20220035275A (ko) | 다발성 골수종 치료 | |
| WO2003084542A1 (en) | Neurotrophic factor production accelerator | |
| JP6987749B2 (ja) | Skチャネル阻害剤による学習障害および他の神経障害の治療 | |
| JP2008520649A (ja) | グリコーゲンシンターゼキナーゼ−3阻害剤 | |
| Perveen et al. | Charcot-Marie-Tooth type 1A disease from patient to laboratory |